Virtual conference

Cyteir Therapeutics to Attend Wedbush PacGrow Healthcare 2022 Virtual Conference

LEXINGTON, Massachusetts, August 01, 2022–(BUSINESS WIRE)–Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetic lethal cancer therapies, today announced that its President and Chief management, Markus Renschler, MD, will participate in the Wedbush PacGrow Healthcare 2022 Virtual Conference on August 9, 2022.

Wedbush PacGrow Healthcare Conference 2022
When: Tuesday, August 9
Time: 12:00 p.m. EDT
Panel: Lethal Synthetic (Weapon) – Part 1

A live webcast of the Wedbush roundtable will be available in the Investors and Media section of Cyteir’s website at www.cyteir.com. A webcast will also be available on the website shortly after the event ends for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company focused on the discovery and development of next-generation synthetic lethal therapies to treat cancer. At Cyteir, we use an integrated approach to target discovery that integrates critical evaluation of target biology with internal and external information from a variety of synthetic genetic and chemical lethality screens to power our discovery and development pipeline. of drugs. Cyteir’s 100%-owned lead compound, CYT-0851, is a selective oral investigational drug currently in Phase 1/2 clinical trials for hematological malignancies and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter and to www.cyteir.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220801005239/en/

contacts

INVESTORS:
Lisa Hayes
Vice President, Investor Relations and Corporate Communications
908-868-8926
[email protected]

MEDIA:
Michele Parisi
925-429-1850
[email protected]